Ads
related to: drugs for bronchial asthma classification list- Adverse Reactions
Learn About The Adverse Reactions
Of This Daily Asthma Treatment.
- Dosing Information
HCPs: See The Dosing Information Of
This Once-Daily Asthma Inhaler.
- Samples & Savings
Request Samples For Your Practice
Daily Triple Therapy Asthma Option.
- Formulary Coverage
See If Your Patients Are Covered
With This Daily Asthma Treatment.
- Resources & Information
Access Resources & Important Info
For An Asthma Therapy Here.
- Important Safety Info
Read About Safety & Side Effects
For An Asthma Triple Therapy.
- Adverse Reactions
Search results
Results From The WOW.Com Content Network
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
They are primarily used to treat asthma and other pulmonary disorders. Bronchodilators are considered an important treatment regime for chronic obstructive pulmonary disease (COPD) and are usually used in combination with short acting medications and long acting medications in a combined inhaler. [1] [2]
These drugs are used for the treatment of asthma. They may be useful either in the treatment or prevention of asthma attacks. Subcategories.
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction.
The proposed mechanism is that while LABAs relieve asthma symptoms, they can also promote bronchial inflammation and sensitivity without warning. [23] On February 18, 2011, the FDA issued a safety alert for long-acting β agonists. [24]
Ad
related to: drugs for bronchial asthma classification list